Pfizer has defeated an asbestos case involving a product made by a now-bankrupt subsidiary after a Maryland judge ruled that an exception to the shield that bankruptcy law provides to defendants doesn’t apply to the plaintiff’s case.
When Pfizer’s subsidiary Quigley Company, Inc., reorganized as part of its bankruptcy, all asbestos lawsuits against it now are channeled into an asbestos trust seeded initially with nearly $1 billion. But one plaintiff tried to argue that Pfizer Inc. was still liable in civil court by arguing Pfizer was the apparent manufacturer of a heat-resistant, refractory product known as Insulag that was designed, manufactured and sold by Quigley.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
